Crucell N.V. (acquired by Johnson and Johnson)

Corporate Snapshot

Crucell N.V. is a biopharmaceutical company that employs proprietary technology to discover, develop, manufacture, and commercialize vaccines and antibodies targeted at a variety of infectious diseases. The Company utilizes a human cell line production system called PER.C6®, which may facilitate products with greater safety, efficacy, and cost-efficiency than those currently marketed. Crucell is developing vaccines to treat and prevent influenza, Ebola, West Nile virus, and malaria, and is in the discovery stage with a tuberculosis (TB) vaccine and antibodies for rabies and Severe Acute Respiratory Syndrome (SARS). Crucell works with sanofi aventis SA (SNY-NYSE) to develop and commercialize its influenza vaccine; has a Collaborative Research and Development Agreement (CRADA) and vaccine production contract in place with the U.S. National Institutes of Health (NIH) for its Ebola vaccine; and is working with GlaxoSmithKline PLC (GSK-NYSE), New York University (NYU), and the Walter Reed Army Institute of Research (WRAIR) to develop its malaria vaccine, which has been funded up to the clinic by the National Institute of Allergy and Infectious Diseases (NIAID).

Johnson & Johnson completed the tender offer for Crucell N.V. (Crucell) on February 22, 2011 and declared the offer unconditional. As a result, Crucell will now operate as the center for vaccines within the Johnson & Johnson pharmaceuticals group.